ofatumumab
Showing 1 - 25 of 68
Neuromyelitis Optica Spectrum Disorder Trial in Xi'an (Ofatumumab)
Recruiting
- Neuromyelitis Optica Spectrum Disorder
- Ofatumumab
-
Xi'an, Shaanxi, ChinaTangdu Hospital
Aug 16, 2022
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute
Active, not recruiting
- Small Lymphocytic Lymphoma
- CLL (Chronic Lymphocytic Leukemia)
- Fludarabine Phosphate
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 6, 2022
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab
Recruiting
- Relapsing Remitting Multiple Sclerosis
- Ofatumumab
-
Los Angeles, CaliforniaUniversity of Southern California
Feb 3, 2022
Ocrelizumab and Ofatumumab Administration in Relapsing Multiple
Terminated
- Relapsing Forms of Multiple Sclerosis
- Ocrelizumab
- Ofatumumab
-
Lutherville, Maryland
- +1 more
Feb 28, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ofatumumab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ofatumumab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 23, 2022
Multiple Sclerosis Trial in Germany (Ofatumumab)
Active, not recruiting
- Multiple Sclerosis
- Ofatumumab
-
Berlin, Germany
- +5 more
Aug 5, 2022
Immune Cells and Meningeal Lymphatic Drainage in Demyelinating
Not yet recruiting
- Multiple Sclerosis
- +2 more
- Ofatumumab
-
Tianjin, Tianjin, ChinaTianjin Medical University General Hospital
Jun 15, 2022
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Ofatumumab
- +2 more
-
Phoenix, Arizona
- +3 more
Jul 20, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,
Completed
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- High Dose Methylprednisolone (HDMP)
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Apr 2, 2021
Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- [F-18]PBR06
-
Boston, MassachusettsPartners MS Center, 60 Fenwood Road
Jul 20, 2021
Relapsing Multiple Sclerosis Trial in United States (Quadrivalent influenza vaccine, Ofatumumab)
Recruiting
- Relapsing Multiple Sclerosis
- Quadrivalent influenza vaccine
- Ofatumumab
-
Phoenix, Arizona
- +3 more
Aug 30, 2021
Relapsing Multiple Sclerosis Trial in Puerto Rico, United States (Ofatumumab)
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
-
Birmingham, Alabama
- +16 more
Mar 22, 2022
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jun 3, 2021
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma Trial in
Active, not recruiting
- Stage I Mantle Cell Lymphoma
- +4 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Buffalo, New York
- +1 more
Mar 9, 2022
Chronic Lymphocytic Leukemia Trial in Cologne (Bendamustine, Ofatumumab, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Jun 9, 2020
Nephrotic Syndrome Trial in Genoa (Ofatumumab, Placebo)
Terminated
- Nephrotic Syndrome
- Ofatumumab
- Placebo
-
Genoa, Italy/GE, ItalyIRCCS Istituto Giannina Gaslini
Jul 28, 2020
Nephrotic Syndrome Trial in Genoa (Ofatumumab, Rituximab)
Completed
- Nephrotic Syndrome
- Ofatumumab
- Rituximab
-
Genoa, Italy/GE, ItalyIRCCS Istituto Giannina Gaslini
Jul 28, 2020
Multiple Sclerosis Trial in Worldwide (Ofatumumab, First line DMT)
Recruiting
- Multiple Sclerosis
- Ofatumumab
- First line DMT
-
Bayonne, Bayonne Cedex, France
- +42 more
Jul 25, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Duvelisib, Ofatumumab)
Completed
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Duvelisib
- Ofatumumab
-
La Jolla, California
- +91 more
Dec 14, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (IPI-145 (duvelisib), Ofatumumab)
Completed
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- IPI-145 (duvelisib)
- Ofatumumab
-
La Jolla, California
- +68 more
Mar 15, 2021
Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia Trial in Houston (drug,
Completed
- Acute Lymphoblastic Leukemia
- +6 more
- Cyclophosphamide
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Apr 6, 2021
B-cell Lymphoid Leukemia, Young Patients Trial in Italy (Cyclophosphamide, Fludarabine, Ofatumumab)
Completed
- B-cell Lymphoid Leukemia
- Young Patients
- Cyclophosphamide
- +2 more
-
Alessandria, Italy
- +21 more
Oct 12, 2020
Chronic Lymphocytic Leukemia, Fatigue, Fever Trial in Houston (Lenalidomide, Ofatumumab)
Completed
- Chronic Lymphocytic Leukemia
- +9 more
- Lenalidomide
- Ofatumumab
-
Houston, TexasM D Anderson Cancer Center
Apr 16, 2019
Non-Hodgkin's Lymphoma Trial in Grand Island, Omaha (Lenalidomide, ofatumumab)
Completed
- Non-Hodgkin's Lymphoma
- Lenalidomide
- ofatumumab
-
Grand Island, Nebraska
- +1 more
Feb 20, 2019